Reed E, Papp J, Oh Y, LeVine K, Tarabichi Y, Bastian E
J Am Coll Emerg Physicians Open. 2024; 5(5):e13304.
PMID: 39445120
PMC: 11496383.
DOI: 10.1002/emp2.13304.
Smart R, Powell D, Pacula R, Peet E, Abouk R, Davis C
J Health Econ. 2024; 97:102917.
PMID: 39043099
PMC: 11392605.
DOI: 10.1016/j.jhealeco.2024.102917.
Cerda M, Hamilton A, Hyder A, Rutherford C, Bobashev G, Epstein J
Epidemiology. 2024; 35(3):418-429.
PMID: 38372618
PMC: 11495844.
DOI: 10.1097/EDE.0000000000001703.
Tsui J, Gojic A, Pierce K, Tung E, Connolly N, Radick A
Drug Alcohol Depend Rep. 2024; 10:100213.
PMID: 38261893
PMC: 10796962.
DOI: 10.1016/j.dadr.2023.100213.
Picco L, Jung M, Cangadis-Douglass H, Lam T, Nielsen S
Pharmacy (Basel). 2023; 11(5).
PMID: 37888509
PMC: 10609676.
DOI: 10.3390/pharmacy11050164.
Temporal Reinforcement of Naloxone Training Results in Significant Retention of Anti-bias and Overdose-Response Knowledge.
Bharne P, Kelly E, Rajkumar S, Iglesias A, Ponnapalli S, Haslund-Gourley B
Cureus. 2023; 15(9):e45415.
PMID: 37854753
PMC: 10581504.
DOI: 10.7759/cureus.45415.
Readiness of community pharmacies to implement an opioid safety intervention.
Floyd A, Silcox J, Cousin E, Irwin A, Gray M, Bolivar D
J Am Pharm Assoc (2003). 2022; 63(1):275-283.e1.
PMID: 36496310
PMC: 9870924.
DOI: 10.1016/j.japh.2022.10.031.
A longitudinal study of naloxone opioid overdose awareness and reversal training for first-year medical students: specific elements require reinforcement.
Sandhu R, Heller M, Buckanavage J, Haslund-Gourley B, Leckron J, Kupersmith B
Harm Reduct J. 2022; 19(1):70.
PMID: 35780103
PMC: 9250225.
DOI: 10.1186/s12954-022-00656-y.
Study protocol for the Respond to Prevent Study: a multi-state randomized controlled trial to improve provision of naloxone, buprenorphine and nonprescription syringes in community pharmacies.
Green T, Bratberg J, Irwin A, Boggis J, Gray M, Leichtling G
Subst Abus. 2022; 43(1):901-905.
PMID: 35213293
PMC: 9720900.
DOI: 10.1080/08897077.2021.2010162.
A systematic review of strategies to improve appropriate use of opioids and to reduce opioid use disorder and deaths from prescription opioids.
Furlan A, Carnide N, Irvin E, Van Eerd D, Munhall C, Kim J
Can J Pain. 2022; 2(1):218-235.
PMID: 35005381
PMC: 8730669.
DOI: 10.1080/24740527.2018.1479842.
Naloxone's role in the national opioid crisis-past struggles, current efforts, and future opportunities.
Bennett A, Elliott L
Transl Res. 2021; 234:43-57.
PMID: 33684591
PMC: 8327685.
DOI: 10.1016/j.trsl.2021.03.001.
The status of naloxone in community pharmacies across Canada.
So R, Al Hamarneh Y, Barnes M, Beazely M, Boivin M, Laroche J
Can Pharm J (Ott). 2020; 153(6):352-356.
PMID: 33282025
PMC: 7689620.
DOI: 10.1177/1715163520958435.
The Opioid-overdose Reduction Continuum of Care Approach (ORCCA): Evidence-based practices in the HEALing Communities Study.
Winhusen T, Walley A, Fanucchi L, Hunt T, Lyons M, Lofwall M
Drug Alcohol Depend. 2020; 217:108325.
PMID: 33091842
PMC: 7533113.
DOI: 10.1016/j.drugalcdep.2020.108325.
Evaluation of naloxone furnishing community pharmacies in San Francisco.
Nguyen A, Kearney T, Apollonio D
J Am Pharm Assoc (2003). 2020; 60(6):1050-1057.e1.
PMID: 32948461
PMC: 7655520.
DOI: 10.1016/j.japh.2020.08.032.
Medication treatment for opioid use disorder and community pharmacy: Expanding care during a national epidemic and global pandemic.
Cochran G, Bruneau J, Cox N, Gordon A
Subst Abus. 2020; 41(3):269-274.
PMID: 32697171
PMC: 7444094.
DOI: 10.1080/08897077.2020.1787300.
Assessing pharmacy-based naloxone access using an innovative purchase trial methodology.
Pollini R, Joyce R, Ozga-Hess J, Xuan Z, Green T, Walley A
J Am Pharm Assoc (2003). 2020; 60(6):853-860.
PMID: 32651116
PMC: 7655699.
DOI: 10.1016/j.japh.2020.05.016.
Revisiting pharmacy-based naloxone with pharmacists and naloxone consumers in 2 states: 2017 perspectives and evolving approaches.
Green T, Donovan E, Klug B, Case P, Baird J, Burstein D
J Am Pharm Assoc (2003). 2020; 60(5):740-749.
PMID: 32334964
PMC: 10948012.
DOI: 10.1016/j.japh.2020.03.005.
Implementation of an Opioid Overdose and Naloxone Distribution Training in a Pharmacist Laboratory Course.
Kwon M, Moody A, Thigpen J, Gauld A
Am J Pharm Educ. 2020; 84(2):7179.
PMID: 32226065
PMC: 7092781.
DOI: 10.5688/ajpe7179.
Preliminary Investigation of Pharmacist-Delivered, Direct-to-Provider Interventions to Reduce Co-Prescribing of Opioids and Benzodiazepines among a Medicare Population.
Bingham J, Taylor A, Boesen K, Axon D
Pharmacy (Basel). 2020; 8(1).
PMID: 32098068
PMC: 7151683.
DOI: 10.3390/pharmacy8010025.
Association between state Medicaid expansion status and naloxone prescription dispensing.
Sohn M, Talbert J, Delcher C, Hankosky E, Lofwall M, Freeman P
Health Serv Res. 2020; 55(2):239-248.
PMID: 32030751
PMC: 7080392.
DOI: 10.1111/1475-6773.13266.